|Day Low/High||113.25 / 113.54|
|52 Wk Low/High||34.53 / 114.20|
Multi-year collaboration focuses on selecting adeno-associated virus vectors to target debilitating genetic diseases in cells of the retina, liver and central nervous system
Statistically Significant Results for Visual Field Highlighted for the First Time
Free Genetic Test Helps Eligible Patients in U.S. Affected by Certain Progressive Retinal Diseases Get Support and Information
Cramer says be prepared to sell the food group because it is getting too difficult to gauge.
When the market decides only one thing is working, that makes things treacherous for everyone else,
First four subjects all with follow up beyond 12 weeks without any need for immunosuppression
MIT's Smart 50 list recognizes companies for their combination of innovative technology and effective management, and it includes 13 pharmaceutical and biotech firms this year.
Trade-Ideas LLC identified Spark Therapeutics (ONCE) as a strong on high relative volume candidate
Study provides insight into long-term safety and durability of effect of contralateral-eye administration in subjects with childhood-onset blindness caused by RPE65 mutations
Cramer says you're in good shape with Dominion Resources, but he is avoiding Freeport-McMoRan.
Investors re-evaluated what stocks are actually worth and started buying, Cramer says.
Trade-Ideas LLC identified Spark Therapeutics (ONCE) as a weak on high relative volume candidate
Trade-Ideas LLC identified Spark Therapeutics (ONCE) as a pre-market mover with heavy volume candidate
Company also will provide an update on preclinical data on SPK-FVIII for the treatment of Hemophilia A
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.